In Vivo CRISPR Therapy Shows Significant Efficacy in Phase 3 Trial for Hereditary Angioedema

The first Phase 3 trial for an in vivo CRISPR therapy targeting hereditary angioedema has concluded with positive results. The study demonstrated an 87% reduction in attacks for patients, with a majority becoming attack-free. This development, published in The New England Journal of Medicine, represents a significant advance in treating this rare swelling disorder.